Atrial Fibrillation and Premature Atrial Complexes in Patients With Ischemic Stroke. (Pacific)

October 10, 2017 updated by: Kristina Hoeg Vinther, Odense University Hospital

Atrial Fibrillation and Premature Atrial Complexes in Patients With Ischemic Stroke: Prevalence, Characteristics and Prognosis

The purpose of this study is to improve secondary prevention of ischemic stroke patients by

  1. Estimating prevalence and the prognostic significance of frequent premature atrial complexes in ischemic stroke patients in relation to death, recurrent stroke and atrial fibrillation.
  2. Characterize ischemic stroke patients by

    1. Echocardiographic characteristics
    2. Biochemical markers
    3. Plaque composition in the carotid arteries

      • in order to improve risk stratification.

Study Overview

Detailed Description

Patients with atrial fibrillation (AF) have a five-fold increased risk of ischemic stroke compared to the general population. Identifying AF can be challenging, but prolonged rhythm monitoring of ischemic stroke patients have shown to enhance detection rates of AF. Therefore it is important to identify predictors of AF to allow targeted screening of patients after ischemic stroke and thereby reduce the recurrent stroke rate. Few former studies have shown an association between excessive numbers of premature atrial complexes (PACs) and AF.

The study population of ischemic stroke patients will at admission undergo following examinations:

  1. ECG
  2. 48 hours inpatient cardiac telemetry (If not known AF)
  3. 24 hours holter monitoring (if not known AF)
  4. echocardiogram
  5. blood sample
  6. CT scan of carotid arteries with contrast made on Dual Energy CT scan.

In the follow-up period, patients will have two visits with 48 hour holter monitoring (after 6 and 12 months, respectively) It will be noticed if patients have any recurrent events, die og developing AF.

The study population will be divided into four groups as follows:

  1. patients with new AF at admission
  2. patients with known AF
  3. patients with frequent PACs
  4. patients without frequent PACs. These groups will be compared on baseline characteristics and on outcome as mentioned.

The overall perspective is to make better strategies for detecting occult AF after ischemic stroke to improve secondary stroke prevention care.

Study Type

Observational

Enrollment (Actual)

264

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Funen
      • Svendborg, Funen, Denmark, 5700
        • Department of Medical Research, OUH, Svendborg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Ischemic stroke patients admitted to the hospital

Description

Inclusion Criteria:

  • admitted with ischemic stroke at a single center
  • time from diagnose to inclusion maximum 7 days.
  • written informed consent or surrogate informed consent eligible
  • age > 18 years.

Exclusion Criteria:

  • hemorrhagic stroke
  • terminal illness and expected lifespan of less than 6 months.
  • any physical or mental condition which make the patients unsuitable for participation in the study.
  • known with a pacemaker
  • anticoagulation treatment of other reasons than atrial fibrillation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Ischemic stroke patients
Patients admitted with ischemic stroke from march 2012 to april 2014

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
time to death and recurrent stroke
Time Frame: Up to 4 years
Up to 4 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to death, recurrent stroke and atrial fibrillation
Time Frame: Up to 4 years
Up to 4 years
Left atrial volume and function estimated by echocardiography
Time Frame: baseline
descriptive comparison in between groups.
baseline

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
biochemical markers
Time Frame: baseline
descriptive comparison in between groups
baseline
Plaque analysis i the carotid arteries on CT
Time Frame: baseline
descriptive comparison in between groups.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2012

Primary Completion (ACTUAL)

August 1, 2015

Study Completion (ACTUAL)

October 1, 2016

Study Registration Dates

First Submitted

July 1, 2014

First Submitted That Met QC Criteria

July 1, 2014

First Posted (ESTIMATE)

July 2, 2014

Study Record Updates

Last Update Posted (ACTUAL)

October 11, 2017

Last Update Submitted That Met QC Criteria

October 10, 2017

Last Verified

October 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

3
Subscribe